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Somatic cells can be reprogrammed into induced pluripotent stem cells (iPSCs) by 
ectopically overexpressing the transcription factors OCT4, SOX2, KLF4 and c-Myc. This 
technique has since its invention been a topic of intense research and hold great promise 
for use in biomedicine. However, the reprogramming process itself remains inefficient 
and slow. Recently CRISPR/Cas9-mediated gene activation (CRISPRa) has been 
employed for the reprogramming of the human somatic cells into iPSCs. CRISPRa has 
proven advantageous in many aspects, such as the ability to activate many genes 
simultaneously and endogenously. In this method, precisely targetable guide RNAs 
mediate an enzymatically inactive mutant of Cas9, nuclease-dead Cas9 (dCas9)-initiated 
activation of the target sequence through a transactivator protein. However, CRISPRa 
still needs to be optimized as it is not very efficient. For optimizing the CRISPRa method, 
we need to target additional endogenous genomic sequences which are known to be able 
to increase reprogramming efficiency. Prior CRISPRa screen, carried out by the 
Otonkoski research group, identified enrichment of genes KLF2, KLF5 and KLF17, 
which are expected to increase reprogramming efficiency. In addition, Otonkoski and his 
group did a single cell RNA sequencing at different time points during reprogramming, 
which identified two of the expressed candidate genes: epithelial cell adhesion molecule 
(EpCAM) and ZNF486.  
 
The aim of this thesis was to validate the enriched guides of KLF2, KLF5 and KLF17 for 
their endogenous gene activation efficiency, and to create and validate functional guides 
for the endogenous activation of EpCAM and ZNF486. In addition, our task was to define 
the effect the expression of these guides have in the pluripotent reprogramming process.  
 
The results of this thesis describe endogenous gene activation of targeted sequences using 
synthesized guides, with a correlation between efficiency and the distance to the gene 
promoter site. Additionally, while the reprogramming of human foreskin fibroblast cells 
using CRISPRa was successful, the incorporation of guides for EpCAM in the cell 
populations did not increase the efficiency of the reprogramming process. In fact, the 
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AP    Alkaline phosphatase 
bp     Base pairs  
Cas    CRISPR associated protein  
cDNA     Complementary DNA  
CRISPR  Clustered Regularly Interspaced Short Palindromic 
Repeats  
CRISPRa    CRISPR activation 
crRNA    CRISPR RNA 
DD     Dihydrofolate reductase-derived destabilisation domain  
DMSO    Dimethyl sulfoxide  
DNA     Deoxyribonucleic acid  
EB     Embryoid body  
EBNA    Eppstein-Barr virus nuclear antigen  
E. coli     Escherichia coli 
EDTA    Ethylenediamine-tetraacetic acid  
EEA     EGA-enriched Alu element motif 
EMT     Epithelial to mesenchymal transition 
EpCAM   Epithelial Cell Adhesion Molecule  
ESC     Embryonic stem cell  
E8     Essential 8 medium  
et al.     And others (“et alteri”)  
Fw     Forward  
GFP     Green fluorescent protein 
gRNA     Guide RNA  
HEK293    Human embryonic kidney cells 293  
HFF     Human foreskin fibroblast  
H3K27ac    Histone H3 lysine 27 acetylation mark  
H3K27me3   Histone H3 lysine 27 trimethylation mark  
H3K9me3    Histone H3 lysine 9 trimethylation mark  
H3K4    Histone H3 lysin 4 methylation mark  
ICC     Immunocytochemistry  
iPSC     Induced pluripotent stem cell  
KLF    Krüppel-like factor 
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LCL     Lymphoblastoid cell line  
M     Molar (mol/l) 
MET     Mesenchymal to epithelial transition 
miRNA    Micro RNA  
miR     Micro RNA  
mRNA    Messenger RNA  
OCT4    Octamer binding protein 4  
OriP    Origin of plasmid replication 
PAM    Protospacer adjacent motif 
PCR     Polymerase chain reaction  
PFA    Paraformaldehyde pH  
Phusion Pyrococcus-like enzyme fused with processivity-
enhancing domain  
Rv    reverse  
RNA     Ribonucleic acid  
ROCK    Rho-associated protein kinase  
Rpm    Revolutions per minute 
RT    Room temperature  
RT-qPCR Quantitative reverse transcription polymerase chain 
reaction  
scRNA-seq    Single cell RNA sequencing  
sgRNA    Single guide RNA  
SOX2  Sex-determining region Y-box containing Transcription 
factor 2  
TAE     Tris-acetate-EDTA-buffer  
TBE     Tris-borate-EDTA-buffer  
TMP     Trimethoprim 
tracrRNA    Trans-activating RNA  
Tris     Tris-(hydroxymethyl)- aminomethane  
VP     Viral protein 






1.1 Pluripotent stem cells 
Stem cells are classified as cells that can both differentiate into other types of cells and 
divide to produce more stem cells (Romito and Cobellis, 2016). After zygote formation 
the first cells forming the morula are totipotent stem cells, going onward to form the 
embryonic and placental tissues (Condic, 2014). The cells forming the embryo further 
differentiate into pluripotent stem cells, leaving behind the ability to form placental 
tissues (Condic, 2014). Pluripotency is a transient state in vivo, and the pluripotent cells 
soon differentiate into different adult tissues, losing their pluripotency (Condic, 2014). 
However, pluripotent stem cells can be derived from the early embryo and maintained 
indefinitely in vitro (Evans & Kaufman, 1981; Thomson et al., 1998). Formerly human 
pluripotent stem cells used in biomedical research have been obtained from embryonic 
tissues, destroying the embryo in the process (de Wert and Mummery, 2003). For this 
reason, the use of embryonic stem cells was limited and controversial. This problem has 
fortunately been alleviated by the development of method for obtaining induced 
pluripotent stem cells (iPSCs) from somatic cells by pluripotent reprogramming 
(Takahashi and Yamanaka, 2006; Takahashi et al., 2007; Yu et al., 2007). 
 
 
1.2 Pluripotent reprogramming 
Pluripotent reprogramming is the process of turning somatic cells into induced pluripotent 
stem cells by introducing a specific set of reprogramming factors into the cells (Takahashi 
and Yamanaka, 2006; Takahashi et al., 2007; Yu et al., 2007). The first set of transcription 
factors for inducing pluripotency, developed by Takahashi and Yamanaka in 2006, 
consisted of octamer-binding transcription factor 4 (Oct4), sex determining region Y-box 
2 (Sox2), krüppel-like factor 4 (Klf4) and c-Myc (Takahashi and Yamanaka, 2006). The 
combination of these factors is also known as OSKM, deriver from the genes’ names’ 
first letters. Later, Thomson et al. developed another set of factors which used LIN28 and 
NANOG instead of KLF4 and C-MYC, named Thomson factors (Yu et al., 2007). These 
generated iPSCs are indistinguishable from embryonic stem cells and likewise are 
pluripotent (Takahashi and Yamanaka, 2006) and the experiments have since sparked 
intense research in the field. Generation of iPSCs has many applications within disease 
modeling, regenerative medicine and immunotherapy, while overcoming the major ethic 
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drawbacks prevalent in embryonic stem cell research (Kiskinis and Eggan, 2010). For 
example, iPSCs are unique to the host, as they can be derived from patients own somatic 
cells, bypassing immune rejection (Kiskinis and Eggan, 2010). Generating iPSCs also 
does not require an embryo to work with, as they can be made from many types of somatic 
cells (Kiskinis and Eggan, 2010). To this date, a vast amount of different methods of 
inducing pluripotency have been described, including: different transcription factors, 
small molecules and chemicals, and mRNAs (Anokye-Danso et al., 2012; Jere Weltner, 
2018a).  However, the current methods for inducing pluripotency are still far from perfect 
(Weltner, 2018a). For example, iPSCs may contain some epigenetic marks and possible 
unwanted residues from the reprogramming process that can affect their differentiation 
and use in disease modelling (Chin et al., 2012; Halevy and Urbach, 2014). Furthermore, 
the inefficiency of this process still remains a major hindrance in pluripotent 
reprogramming, with most methods only inducing pluripotency in only a fraction of cells 
(Malik and Rao, 2013). 
 
 
1.3 Reprogramming phases 
Cellular reprogramming occurs in a multistep, albeit dynamic, process which is typically 
thought to happen in two waves: A stochastic first wave acting to suppress somatic genes, 
and a more deterministic second wave that activate and maintain the expression of 
pluripotency-related genes (Polo et al., 2012). Following a binding of core 
reprogramming factors to distal enhancer sequences, and later to promoter regions, C-
Myc begins the first transcriptional wave (Soufi et al., 2012). The first three days of the 
first transcriptional wave facilitate a rapid proliferation of the cells, which also seems to 
support the self-renewal and maintenance of the iPSCs (Hansson et al., 2015; Polo et al., 
2012). This also increases energy demand, and the cell metabolism changes from 
oxidative phosphorylation to glycolysis (Folmes et al., 2011; Nishimura et al., 2019). In 
addition, factors regulating chromatin organization and RNA processing are upregulated 
in this early process (Buganim et al., 2013; Hansson et al., 2015) 
After this, the second transcriptional wave occurs with Klf4 working with Oct4 and Sox2 
to promote the pluripotent gene expression (Chronis et al., 2017; Polo et al., 2012). This 
then leads to a more deterministic and hierarchical cell changes and establishes the core 




1.4 Mesenchymal-to-epithelial transition (MET) in reprogramming  
Epithelial-to-mesenchymal transition (EMT) is a developmental process initiated earliest 
in the gastrulation stage (R. Li et al., 2010). In EMT, changes in cell contact interactions 
lead to loss of epithelial features in the cell and development of mesenchymal features 
(R. Li et al., 2010). This is mediated through the change in expression of about 4000 
genes, with the most prevalent changes occurring in downregulation of E-cadherin (which 
maintains epithelial cohesion) and upregulation of Snail, in turn repressing epithelial 
regulators (R. Li et al., 2010; Zavadil et al., 2001). EMT is an important process for 
determining cell fate (R. Li et al., 2010), and it is a part of the process in which early 
pluripotent cells develop into mesenchymal ones. As such, the reversion of mesenchymal 
fibroblasts into pluripotent cells have been thought to require the reverse transition, 
mesenchymal-to-epithelial transition (MET). This has been noted to be the case 
(Samavarchi-Tehrani et al., 2010).  
 
Samavarchi-Tehrani et al., (2010) classify the reprogramming to fall into three different 
phases: initiation, maturation and stabilization. They note that the initiation phase 
involves a strong induction of MET, with upregulation of epithelial junctional 
components and epithelial like colonies. One of the important factors facilitating the 
transition from the initiation MET process to the maturation phase is the TGF-b-related 
bone morphogenetic protein (BMP) signaling pathway (Samavarchi-Tehrani et al., 2010). 
BMP pathway works in part by inducing miR(microRNA)-205 and miR-200 with the 
OSKM factors, which promotes MET (Samavarchi-Tehrani et al., 2010). When this 
process was initiated removal of BMP did not halt the reprogramming process 
(Samavarchi-Tehrani et al., 2010). This indicates that BMP is mostly relevant in early 
MET initiation.  
 
Other important components in MET are the TGF-b factors. TGF-b1 is a known EMT 
inducer and has been noted to block reprogramming, as have TGFb2 and TGFb3 (R. Li 
et al., 2010). TGF-b1 has been noted to inhibit the upregulation of epithelial markers, and 
to repress the downregulation of MET-activating Snail (Peinado et al., 2003). The OSKM 
factors seem to reduce the expression of TGF-β factors, with Sox2 and Oct4 suppressing 
TGF-β receptor 3, require for activation of Snail, while Oct4 and Klf4 suppressed TGF-
β3 (R. Li et al., 2010). c-Myc suppressed TGF-β1, providing complete inhibition of the 
TGF-β factors (R. Li et al., 2010). In addition, incompletely reprogrammed cells 
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contained high levels of remaining TGF-β1 and Snail, with low levels of E-cadherin (R. 
Li et al., 2010). Usage of exogenous TGF-β inhibitors also increased reprogramming 
efficiency, further suggesting the direct role of TGF-β factors in EMT and reprogramming 
repression (R. Li et al., 2010). This way, the OSKM factors used in pluripotent 
reprogramming facilitate EMT by repressing pro-MET factors such as TGF-β1 and Snail. 
 
After MET has initiated the reprogramming, removal of the OSKM factors in 5 days 
along the initiation reversed the reprogramming process, meaning that the reprogramming 
is still unstable at this phase (Samavarchi-Tehrani et al., 2010). The maturation phase then 
involved high levels of Nanog and Sall4. When Nanog and Sall4 reached their peak levels 
at day 9, many colonies were able to keep their initiated changes despite discontinuation 
of ectopic OSKM expression (Samavarchi-Tehrani et al., 2010). During the 
reprogramming event, many genes act as barriers to limit the reversal of somatic cells 
into pluripotency (Polo et al., 2012). Many of these genes seem to be active during the 
transition stage between the first and the second wave, and this is thus considered an 




1.5 Epigenetics and barriers of reprogramming 
The purpose of these rate-limiting barriers is to prevent formation of tumors and to keep 
the cell proliferation in check. 
The first reprogramming barrier is caused primarily by the p53 pathway via p21 mediated 
cell cycle arrest (Kawamura et al., 2009). The tumor-suppressing p53 pathway is 
activated by the introduction of reprogramming factors in the cell and inhibits the 
reprogramming of the cells by apoptosis, cell cycle arrest and senescence (Kawamura et 
al., 2009). 
Temporarily downregulating the p53 pathway can increase reprogramming efficiency 
(Kawamura et al., 2009; Zhao et al., 2008). However, as the pathway also protects the 
cell from genome instability, completely turning off the pathway may result in declined 
genomic quality of the iPSCs (Hong et al., 2009; Zhao et al., 2008). 
 
The second barrier in reprogramming is the inaccessibility of the core pluripotency genes, 
as they are packed tightly in inaccessible heterochromatin, caused by repressive DNA 
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and histone modifications, like H3K9me3 or H3K27me3 (Chen et al., 2013; Delgado-
Olguín and Recillas-Targa, 2011). This chromatic structure needs to be remodeled for the 
reprogramming factors to reach their targets (Delgado-Olguín and Recillas-Targa, 2011). 
This can be achieved by removing repressive modifications or adding chromatin opening 
marks like acetyl groups, and by inhibiting histone deacetylases or DNA 
methyltransferases (Delgado-Olguín and Recillas-Targa, 2011; Huangfu et al., 2008). 
In addition, the incomplete transgenic reprogramming often result in a cell-type specific 
memory of the somatic state, which is maintained through differentiation (Lister et al., 
2011; Van Den Hurk et al., 2016). 
 
 
1.6 Reprogramming process in other cell types 
Despite the intense research going into reprogramming fibroblasts, the aspects of the 
reprogramming process cannot be considered universal. There is still a need to determine 
corresponding pathways and dynamics in other cell types. Nefzger et al., (2017) have 
characterized mouse neutrophils and keratinocytes in addition to fibroblasts. These 
experiments show that there are many cell-type specific differences in their pluripotent 
reprogramming, especially in the initiation stage involving cell identity loss (Nefzger et 
al., 2017).  
Furthermore, neither neutrophils or keratinocytes seemed to go through the primitive 
streak-like developmental process which have been described in fibroblasts (Nefzger et 
al., 2017). In addition, despite MET being an important process in fibroblast 
reprogramming, keratinocytes do not require this, as they never pass through the EMT 
differentiation process (Nefzger et al., 2017). The forced expression of OSKM factors 
resulted in mostly cell-type specific changes (Nefzger et al., 2017).  
However these effects also tend to mask a conserved transcription network common to 
all three cell types, with up to half of gene required for pluripotency being highly 
correlated (Nefzger et al., 2017). In addition, all cell types seemed to go through the two 
transcriptional waves described in literature, with the first one coinciding with cell 
identity loss and the second one with pluripotency network reactivation (Nefzger et al., 
2017). Also Egr1 downregulation, central for reprogramming success, appears to be 







There are many different methods of delivering the reprogramming factors into the cells, 
each with their own advantages and drawbacks (Hu, 2014). The methodology for iPSC 
generation can be divided into integrative, that include retroviruses and DNA 
transposons, and non-integrative, including RNA, Sendai viruses, proteins, and episomal 
plasmids (Hu, 2014).  
 
1.7.1 Integrative vectors 
One of the first vectors to be used in pluripotent reprogramming were retroviruses 
(Takahashi and Yamanaka, 2006). These retroviruses have most of their viral genes 
removed, leaving only the ones necessary for gene expression and delivery (Hu, 2014). 
They are most often derived from Moloney Mouse Leukemia Virus γ-retroviral vectors, 
or lentiviruses from HIV (Hu, 2014). The γ-retroviral vectors need a proliferating cell to 
infect, but the lentiviruses can infect non-dividing cells (Kitamura et al., 2003). However, 
retroviral vectors have the problem of uncontrolled genomic integration that might result 
in insertional mutagenesis (Fusaki et al., 2009).  
Adeno-associated virus has also been considered a viable vector for reprogramming, as it 
is non-toxic and capable of long-term transduction also in non-dividing cells (Hu, 2014). 
However, there seems to be a tendency to for AAV to integrate only on cells going 
through reprogramming (J. Weltner et al., 2012). More commonly used Sendai viruses 
also offer a more persistent expression of transgenes due to its episomal replication, with 
no need for repeated transductions (Fusaki et al., 2009). 
 
Integrative transposons can be used for reprogramming, consisting of a vector donor 
plasmid containing the transgenic cargo and terminal repeat sequences, and a helper 
plasmid with the transposase (Wang et al., 2008a). The most typical transposon vectors 
capable of transposing to cells for pluripotent reprogramming are the PiggyBac 
transposon, and the Sleeping Beauty transposon (Wang et al., 2008b). Integrative 
transposons provide a more stable expression of genes, have a larger cargo capacity, and 
can be used to control the temporal expression of transgenes and secondary 
reprogramming of differentiated cells (Woltjen et al., 2009). They also can be removed 





1.7.2  Non-integrative vectors 
Second way to induce pluripotent reprogramming is with episomal plasmid vectors 
(Weltner, 2018a). Because of the transient expression of non-replicating plasmid vectors, 
they needed serial plasmid transfections, and were in efficient (Jia et al., 2010). Later 
replicative episomal plasmid vectors containing oriP and EBNA1 sequences were 
introduced, which removed the need for serial transfections and gave a more persistent 
factor expression (Junying et al., 2009). The oriP and EBNA1 are the origin of replication 
and a protein sequence supporting the function of the oriP and the stability of the plasmid, 
respectively, originating from the Epstein-Barr virus (Yates et al., 2000). These sequences 
facilitate a plasmid replication once per cell cycle, but because of imperfect plasmid 
retention, they over time are removed from the genome, resulting in non-integrative 
reprogramming method (Hu, 2014; Okita et al., 2011). 
Some other used viral vectors are adenovirus or Sendai virus -based episomal viruses 
(Hu, 2014). Adenoviruses have a large cargo capacity, but are typically inefficient, and 
not commonly in use anymore (Hu, 2014). 
 
Reprogramming can be initiated with modified mRNA targeting the reprogramming 
factors (Warren et al., 2010). Transfection of mRNA causes typically an immune 
response, inhibiting growth, and for this reason the mRNA has to be modified by 
inhibiting the immune factors, particularly RIG-I, PKR or TRL7/8 (Seth et al., 2006). In 
addition, alphavirus based episomal RNA vectors can be used. These have the advantage 
of being non-integrative, but can be toxic to the cell (Weltner, 2018a). 
 
Recombinant proteins have been used in reprogramming, and rely on a cell penetrating 
peptide to fuse with the cell and release the cargo (Hu, 2014). This is typically achieved 
with a protein transduction domain, naturally occurring in HIV and herpes simplex virus 





CRISPR (clustered regularly interspaced short palindromic repeats) is a family of 
bacterial DNA sequences originally acting as a bacterial immune system against foreign 
DNA (Kurata et al., 2018). The CRISPR DNA, along with a CRISPR-associated protein 
(Cas) forms the system known as CRISPR-Cas, a method commonly used in genetic 
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engineering. The CRISPR-Cas -system consists of a leader sequence followed by short 
repeats separated by unique spacers (Louwen et al., 2014). The CRISPR-Cas system is 
activated from viral stress and saves the invading DNA particles into the spacers (Louwen 
et al., 2014). These spacer sequences are then transcribed into CRISPR-RNA (crRNA) 
(Kurata et al., 2018). The crRNA joins with a cleaving Cas-endonuclease and targets and 
degrades subsequent invading DNA sequences (Louwen et al., 2014). 
 
This system is now commonly used in genetic engineering, with the most used CRISPR 
subtype relying on a protein Cas9  (Kurata et al., 2018). The Cas9 system consists of the 
Cas9 endonuclease, nuclease targeting CRISPR-RNAs (crRNAs), and a trans-activating 
CRISPR RNA (tracrRNA) (Kurata et al., 2018). In many systems however, the CRISPR 
RNAs are combined into a single-guide RNA (gRNA), which can be easily manipulated 
to target and cut wanted sequences (Kurata et al., 2018). Multiple gRNAs can also be 
concatenated into a single vector to allow for simultaneous targeting of multiple genes 
and is typically achieved by Golden Gate cloning (Weltner, 2018a). 
 
 
1.9 CRISPR gene activation system 
In addition to cutting the DNA, CRISPR-Cas can also be used in targeted gene activation 
(CRISPRa). CRISPRa utilizes catalytically inactivate Cas-protein (dCas9) (Gilbert et al., 
2013). An additional transactivation domain is attached to this dCas9 protein, which 
functions by calling relevant transcription factors, such as the mediator complex and 
Polymerase II, to the gRNA-Cas complex binding site to initiate gene transcription 
(Balboa et al., 2015). Common trans-activation domains used for activation include NF-
kappa B p65 subunit or multiple repeats of HSV1 VP16 peptides, such as in the 
dCas9VP192 -sequence developed by Balboa et al. (2015), which utilizes 12 VP16 
repeats (Weltner, 2018a). The VP192-system can be fused with a doxycycline activated 
TetON-promoter for controlling its activity in the cell (Sokka J, 2019; Weltner, 2018a).  
 
1.1 CRISPRa-reprogramming 
By activating various reprogramming factors in the cell, CRISPRa can be used in 
pluripotent reprogramming. This was demonstrated by Liu et al. in 2018, by using a 
CRISPRa SunTag-activator to reprogram mouse fibroblasts into pluripotency via 
modulating Oct4 and Sox2 (Liu et al., 2018). Additionally, pluripotent reprogramming in 
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human cells was achieved by Weltner et al. via a dCas9-VP192 activator. This was 
achieved solely by targeting the core OSKM pluripotency factors, with the addition of 
Lin28a, but this method remained inefficient. Incorporating an EEA motif targeting to 
CRISPRa-reprogramming has since made the method nearly as effective as earlier 
established methods (Weltner et al., 2018b). The EEA motif is a highly conserved 
sequence in the human genome typically enriched in the promoter areas of genes involved 
in early embryonic development (Töhönen et al., 2015). The enhanced reprogramming is 
thought to be mediated in part by activation of NANOG and REX1 (Warren, 2019; 
Weltner et al., 2018b). 
The CRISPRa -mediated reprogramming has the advantage of being able to induce the 
expression of reprogramming factors within the cell, rather than with forced exogenous 
factors, to effectively initiate the reprogramming process (Balboa et al., 2015). CRISPRa 
can also potentially help bypass the epigenetic barrier in reprogramming by opening areas 
in the genome.  In addition, the guide RNAs for the CRISPRa reprogramming system are 
easy to design and allows the targeting and studying of complex reprogramming factor 
systems and their interactions in the cell. Alternative reprogramming factors can be 
screened for reprogramming potential and individually validated to optimize the 
pluripotent reprogramming outcome.  
 
 
1.10 Guide screening 
Screens were previously carried out by our lab to find candidate genes to enhance the 
reprogramming outcome. This was done by transfecting into cells a library of guide RNAs 
targeting about 40 transcription factors interacting with the pluripotency network. These 
cells were then carried through the reprogramming and the most efficient colonies were 
selected. The selected colonies were then carried through the selection process through 3 
generations, with varying amounts of transfection material. Guides that promote more 
efficient reprogramming are expected to enrich in the reprogrammed iPSC colonies, and 
can be then screened for further evaluation. However, guides can enrich in the colonies 
for other reasons than enhancing the pluripotency, like by chance. To rule out passenger 
guides that are randomly included in the reprogramming colonies, hits from the screen 
must be validated. The thesis work will be focused on validating the hits from a previously 
performed CRISPRa screen for guide RNAs that can enhance reprogramming. The guide 
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RNAs will first be assessed for their efficiency in activating their target genes, followed 
by assessing their effect on pluripotent reprogramming efficiency. 
 
 
1.11 Single cell RNA sequencing 
Additionally, our lab carried out a single-cell RNA analysis to determine expression 
patterns of different genes during pluripotent reprogramming. Two emerging genes of 
interest were the genes Epcam, activating in the later stages of reprogramming, and 
Znf486. 
Single cell RNA sequencing is a method for examining the gene expression at the single 
cell resolution. When analyzing cells in bulk, the varying transcriptomic levels even out. 
Single cell sequencing reveals heterogeneity in seemingly homogenous cell populations, 
with the possibility of identifying sub-populations and characterizing relations within cell 
states.  
To achieve this, cells are suspended into a suspension which disrupts the cell adhesions. 
The cells are then separated with microdroplet separation, where each droplet contains 
the reagents necessary for the sequencing the included singular cell. The cell material is 
lysed, and RNA is reverse transcribed into cDNA, with unique short primers containing 
molecular identifier to track the individual mRNA molecules. The cDNA is amplified an 
additional time to produce cDNA libraries, which can be pooled and sequenced with next 
generation sequencing and analyzed with bioinformatic approaches. This method can 




1.12 iPSC characterization 
To successfully research pluripotent reprogramming, one needs to know if the cells in 
question can reach pluripotency, and whether they actually do so (Martí et al., 2013). This 
is also important for the objective comparison between different pluripotent cell lines 
(Martí et al., 2013). Some of the commonly used methods include immunocytochemistry 
and identification of three germ layers in embryoid bodies (Martí et al., 2013). 
Additionally alkaline phosphatase (AP) -staining can be used to validate the amount of 
pluripotent colonies generated by different samples (Singh et al., 2012).  
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Immunocytochemistry typically aims to detect common pluripotency markers, such as 
OCT4, NANOG, SOX2, TRA-1-60 or TRA-1-81, using secondary antibody binding 
(Nethercott et al., 2011). Immunocytochemistry allows for the detection and localization 
of these markers in cell populations (Nethercott et al., 2011).  
Embryoid bodies are suspended aggregates of stem cells (Lin et al., 2020). In the absence 
of FGF2 these aggregates spontaneously differentiate into all three germ layers, and are 
used in order to both create differentiated cells for research, and to confirm the 
pluripotency of cells (Lin et al., 2020).  
AP-staining takes advantage of the capability for the common enzyme, alkaline 
phosphatase, to change conformation of a colorimetric agent from soluble to precipitated 
state, allowing its visual detection (Martí et al., 2013). Alkaline phosphatase is present in 
many human cells types, and is particularly expressed at high levels in pluripotent stem 
cells (Singh et al., 2012). While it is not a definitive method for defining pluripotent cells, 
it can be used to differentiate iPSCs from non-AP containing differentiated cells (Singh 
et al., 2012).  
 
 
1.13 Pluripotency factors 
The original set of pluripotency factors developed by Takahashi and Yamanaka, 
combining Oct4, Sox2, Klf4 and Myc, are routinely used in pluripotent reprogramming. 
There have been many different combinations of pluripotency factors able to induce 
pluripotency, but Oct4 and Sox2 typically act as central factors in typical reprogramming 
factor sets (Weltner, 2018a). 
 
1.13.1 OCT4 
One of the most important pieces of the core pluripotency factors is the octamer-binding 
transcription factor 4 (Oct4) (Radzisheuskaya and Silva, 2014). Oct4 alone can induce 
pluripotency in mouse neural stem cells, but over expression of Oct4 causes mesodermal 
differentiation and its under-expression causes trophectodermal or endodermal 
differentiation (Kim et al., 2008). Oct4 is expressed in all pluripotent cells, and activates 
in the zygote during embryonic genome activation, facilitating proper embryonic 
development (M. Li and Belmonte, 2018). Oct4 acts by binding with Sox2, forming a 
heterodimer, and maintains pluripotency by promoting self-renewal (M. Li and Belmonte, 
2018). Oct4 has also been demonstrated to facilitate mesenchymal to epithelial transition 
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(MET), and downregulate MET-counteracting factors (Radzisheuskaya and Silva, 2014). 
It is also shown to bind to heterochromatin containing regions and open them, activating 
genes and thus acting as an epigenetic modificator (Gaspar-Maia et al., 2011). It is not 
known to have a role in somatic cells, and its expression is silenced with cell lineage 
commitment (Jaenisch and Young, 2008). Due to its unique binding to Sox2, Oct4 has 
previously thought to be the only reprogramming factor which cannot be replaced by 
other members of its family during pluripotent reprogramming (Radzisheuskaya and 
Silva, 2014). Recently however, reprogramming has been achieved just with SOX2, 
KLF4 and C-MYC, while substituting OCT4 with endoderm lineage specifiers (Velychko 
et al., 2019). 
 
1.13.2 SOX2 
The sex-determining region Y-box 2 (Sox2), binding together with Oct4, is another core 
reprogramming factor in the pluripotency network (Boyer et al., 2005). Like Oct4, it is 
expressed in the early embryo and is required for its proper development by playing a 
part in establishing the inner blastocyst cell mass, as well regulating the development of 
the trophectodermal and extraembryonic endodermal cell lineages (M. Li and Belmonte, 
2018; Sarkar and Hochedlinger, 2013). In addition however, Sox2 also is expressed in 
later embryonic development stages, and facilitates tissue regeneration and adult tissue 
homeostasis (Sarkar and Hochedlinger, 2013). Together with Oct4, Sox2 is thought to 
inhibit differentiation, and Sox2 is also involved in promoting MET (Radzisheuskaya and 
Silva, 2014). Sox2 can be replaced by other Sox-family members, such as Sox1 and Sox3 
to in cellular reprogramming (Sarkar and Hochedlinger, 2013). 
 
1.13.3 KLF4 
Klf4, or Krüppel-like factor 4, is yet another important transcription factor which 
regulates cell proliferation, apoptosis, differentiation, embryonic development and tissue 
homeostasis maintenance (Ghaleb and Yang, 2017). It belongs to the KLF family of zinc 
finger transcription factors, which bind to DNA and control its expression (Ghaleb and 
Yang, 2017). Klf4 is essential for the proper development of mice, and knockdown of 
Klf4 results in prenatal death (Bialkowska et al., 2017).  
Klf4 can be either a transcriptional activator or repressor, and acts as an oncogene with 
both tumor suppressing and promoting qualities (Ghaleb and Yang, 2017). Klf4 is also 
thought to have a role in EMT, either as a suppressor or activator (Ghaleb and Yang, 
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2017), and mediates the interaction of Oct4 and Sox2 (Bialkowska et al., 2017; 
Radzisheuskaya and Silva, 2014). The removal of KLF4 during reprogramming can halt 
the process, which can then be continued by re-introducing KLF4 to the cell (Nishimura 
et al., 2014). KLF4 is furthermore not required for pluripotent reprogramming, but 
increases its effectiveness and speed (Jaenisch and Young, 2008). Klf4 can be replaced 
by Klf2 or Klf5, and simultaneous knockdown of all these genes in ESCs results in 
differentiation (Bourillot and Savatier, 2010). 
 
1.13.4 c-Myc 
The last core factor belonging to the Yamanaka factor cocktail is Myc, also known as c-
Myc. Myc is an oncogene, well known for its role in proliferation of many cells (Hanahan 
and Weinberg, 2011). It joins with MAX to form a heterodimer and binds DNA sequences 
and amplifies gene expression on a wide range (Dang, 2012). While Myc does not itself 
bind to heterochromatin, it is observed to play a part in epigenetic modification by 
effecting the expression of other genes during tumorigenesis (Poli et al., 2018). 
The Myc transcription network is responsible for influencing many cell growth pathways, 
and the Myc network is distinct from the typical core pluripotency circuit (Kim et al., 
2008). Myc acts in these pathways either as an activator or repressor depending on the 
context (Kim et al., 2008). C-MYC increases both speed and efficiency of pluripotent 
reprogramming, but is not mandatory for iPSC generation and can be either omitted or 
replaced by other members of the family (Nakagawa et al., 2010). These includes also L-
MYC and N-MYC. In some cases, L-MYC has proven even more effective in iPSC 




LIN28A and LIN28B are RNA binding transcription factors expressed in pluripotent stem 
cells (M. Li and Belmonte, 2018). Specifically, LIN28A binds to let-7 pre-miRNAs 
blocking their maturation (M. Li and Belmonte, 2018), thus inhibiting their cell cycle 
promoting effects on MYC and Cyclin D1 (Lee et al., 2016; Ruiz et al., 2011). They are 
used in reprogramming, and enhances its effectiveness (Zhang et al., 2016). LIN28A and 
LIN28B are thought to be miRNA regulators with roles in development, cellular 





The epithelial cell-adhesion molecule (Epcam) is a transmembrane glycoprotein present 
in many epithelial tissues, particularly epithelial cancers (L. Huang et al., 2018). It 
mediates cell-to-cell adhesion as well as cell signaling, migration, proliferation and 
differentiation (L. Huang et al., 2018). Epcam has not been noted to be expressed in other 
than epithelial tissues, and its expression is elevated in many advanced carcinomas 
(Patriarca et al., 2012). As such, it can be used as a diagnostic marker. Epcam silencing 
in cancer has been observed to significantly reduce the proliferation and migration of 
epithelial cancer cells (Münz et al., 2004). The role of Epcam in cell proliferation can me 
partly mediated by its ability to rapidly upregulate the oncogene c-Myc (Münz et al., 
2004). In addition, Epcam and its associated protein Cldn7 were noted to be upregulated 
in mouse embryonic fibroblast reprogramming, and that overexpression and inhibition of 
Epcam or Cldn7 resulted in respective enhancement or impairment of the reprogramming 
process (H. P. Huang et al., 2011). This could be caused due to its p53-p21 pathway 
repression, and upregulation of Oct4 (H. P. Huang et al., 2011). Additionally, EpCAM 
and EpEX has been noted to both increase OSKM reprogramming efficiency, but also 
replace multiple OSKM factors (Kuan et al., 2017). Using EpCAM and EpEX, either Klf4 
or Oct4 alone were capable of reprogramming fibroblasts into iPSCs (Kuan et al., 2017). 
 
1.13.7 ZNF486 and zinc-finger proteins 
A zinc finger is a structural protein motif containing one or more stabilizing zinc ions 
(Han et al., 2020). Zinc fingers typically bind to DNA sequences, but also RNA, proteins 
and lipids (Cassandri et al., 2017). This attachment then guides cellular organization, 
development, adhesion, protein folding and, importantly, gene expression (Cassandri et 
al., 2017). Zinc finger proteins are developed into many distinct families with different 
tasks, with two particularly important families in this case being the Krüppel-like factor 
(KLF) family, and Krüppel-associated box (KRAB) containing zinc finger proteins 
(KZFPs). The KZFP family of zinc finger proteins are known to control transposable 
elements in early embryonic development of humans (Pontis et al., 2019). These 
transposable elements can then affect gene expression via KLF stimulation (Pontis et al., 
2019). ZNF486 is one of these zinc finger proteins (Pontis et al., 2019), and while there 
is not much data of ZNF486 functions, it is thought to be activated during pluripotency 
reversal and thus potential gene for affecting pluripotent reprogramming, based on earlier 
screens by our lab. 
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1.13.8 Krüppel-like factors 2, 5 and 17 
Like KLF4, transcription factors KLF2, KLF5 and KLF17 belong to the KLF family of 
zinc finger proteins (Pollak et al., 2018). Particularly KLF2 and KLF5 hold similar 
functions as they can be used to replace KLF4 in reprogramming (Bourillot and Savatier, 
2010). KLF2 is thought to be involved in many processes in human, including lung 
development, epithelial integrity, T-cell differentiation and adipogenesis (Jha and Das, 
2017). It is also implicated to mediate the development of embryonic blood cells and 
blood vessels (Jha and Das, 2017). Likewise, KLF5 is involved in cell proliferation and 
differentiation, and thought to regulate skeletal muscle regeneration, myogenic 
differentiation and mitochondria function among many others (Pollak et al., 2018). 
KLF17 is present in primate inner cell mass alongside NANOG (Blakeley et al., 2015). 
Primed cells lose KLF17 expression (Guo et al., 2016). It acts in the epithelial-
mesenchymal transtition and has an anti-metastatic function in breast cancer (Gumireddy 
et al., 2010). KLF17 is known to interact with p53, where p53 is thought to promote 
KLF17 functions, while KLF17 enhances p53 transcription in a positive feedback-loop 

























2 Aims of the Thesis 
The main aim of this work is to derive a new more efficient way of producing human 
iPSC using CRISPRa. This is done by validating the genes identified from our CRISPRa 
reprogramming guide screen (KLF2, KLF5 and KLF17), and single cell RNA sequencing 
(EpCAM and ZNF486). The specific aims of the work are as follows: 
 
1. Evaluation of selected guide RNAs in activation of their respective target endogenous 
genes in HEK293 cells. 
 
For this aim, target genes will be selected by single cell RNA sequencing, and the 
enrichment of guide RNAs targeting the specific gene resulting from guide screens. Guide 
RNAs selected by single cell RNA sequencing targeting EpCAM and ZNF486 will be 
tested guide by guide for endogenous gene activation efficiency. The guide RNAs 
selected from screens targeting KLF2, KLF5 and KLF17 will be tested guide by guide for 
gene activation efficiency and the results compared to the level of enrichment per guide 
in the reprogramming guide screens.  
 
2. Functional testing of selected gRNAs 
 
For this aim, guides selected in the aim 1. will be tested for their effect in improving 
reprogramming efficiency. This will be done using guides targeting endogenous OSKML 
(OCT4, SOX2, KLF4, MYC and LIN28) as basal reprogramming factors in addition to 
guides targeting genes EpCAM, ZNF486, KLF2, KLF5 and KLF17 each. Another set of 
guides targeting the same genes will also be selected based on their enrichment in the 
reprogramming screen. These two sets will be compared for their effect on 
reprogramming efficiency and for the kinetics of the reprogramming process, measured 





3 Materials and Methods 
 
3.1 Primers and guide assembly 
3.1.1 RT-PCR 
RNA was extracted by first lysing the cells in 350 μl LBP lysis buffer. The lysate was 
then purified using NucleoSpin RNA plus purification kit (Macherey-Nagel), according 
to manufacturer’s instructions. RNA concentrations were measured with Simplinano 
spectrophotometer. One microgram of RNA was denatured in 65 C for 1 min and 
synthesized into cDNA by reverse transcription. RT master mix was firstly created (dNTP 
0.3 mM, Oligo dT primer 5 µM, Random primers 0.1 µg, Ribolock RNAse inhibitor 20U, 
M-MLV reverse transcriptase 100U in M-MLV Reverse transcriptase buffer, total 
volume 8.7 µl). Molecular biology grade water (Lonza) was used in all PCR reactions. 
To each 1 µg of denatured sample RNA, water was added to a total of 11.3 μl. 8.7 μl of 
RT master mix was added on samples for a total volume of 20 μl, which were then 
incubated at 37 °C for 90 min. Enzyme was denatured at 90 °C for 5 min.  
 
3.1.2 qPCR 
Gene expression was quantified in 20 μl qPCR reactions. A master mix containing 4 μl 
5x HOT FIREPol EvaGreen qPCR Mix Plus (ROX) (Solis Biodyne) reagent and 10 μl 
water per reaction. 1 μl of sample DNA was added per reaction. Qiagen QIAgility 
pipetting robot was used to pipet 5 μl 2 mM forward and reverse primers (Table 1.) diluted 
in water to 15 μl of sample mix, making two technical replicates for each reaction. The 
reaction cycle was run in Qiagen Rotor-Gene Q qPCR machine for at 95 C for 15 min, 
after which temperatures 95 C for 25 s, 61 C for 25 s, and 72 C for 25 s was cycled for 
35 cycles. 
 
Table 1. qPCR primers for ZNF486 and EpCAM 
qPCR 
primers 




ZNF486 5’GCTTTTTAAGGAAGTTCTCAACCC 5’GAACTTGTTACAGGCTTGCCA 59 95 
EpCAM  5’GCGAGTGAGAACCTACTGGA 5’AACGCGTTGTGATCTCCTTCT 59 110 
 
After qPCR, the reactions’ melting curve was analyzed by increasing the temperature 




3.1.3 gRNA design 
gRNAs were designed using Benchling sequence design tools (Benchling [Biology 
Software]. (2019). Retrieved from https://benchling.com). The upstream region of the 
genes between -50 and -500 bp from the transcription start site was targeted, and 5 gRNAs 
for each gene were made (Table 2.). gRNAs expression cassettes were then assembled 
using PCR (dNTP 0.2 mM, 1 aggc Forward Primer 0.5 μM, 1 aggc Reverse Primer 0.5 μM, 
Phusion polymerase 0.02U, U6 tailed promoter 5 ng, tracR tailed template 5 ng and gRNA 
oligos 0.02 µM in HF buffer according to manufacturer’s instructions, total volume 100 µl). 
 




































The reaction was run on 98 C for 3 min after which temperatures 98 C for 10 sec, 52 
C for 30 sec and 72 C for 12 sec were cycled 35 times. Reaction was ended with 72 C 
for 8 min. Successful assembly of cassettes was confirmed with electrophoresis in 1.5 % 
agarose gel in TBE. Products were purified using NucleoSpin Gel and PCR clean-up kit 
(Macherey-Nagel). (Balboa et al., 2015) 
 
 
3.1.4 HEK293 Transfection for guide validation 
To test the gene activation levels of guide RNAs, HEK293 cells were seeded on 24-well 
plates on MEF media 100 000 cells per well. The next day the cells were transfected with 
400 ng of CRISPR-Cas activator plasmid DNA, 200 ng of constructed guide RNA, 10 μl 
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water and 3.6 μl Fugene -transfection reagent for a total of 25 μl reaction. The cell RNA 
was then purified using NucleoSpin RNA purification kit (Macherey-Nagel). 
 
3.2 Plasmid preparation 
3.2.1 Golden gate assembly for EpCAM and ZNF486 
To prepare for the Golden gate-ligation, guides were assembled using linker primers 
(dNTP 0.2 mM, Phusion polymerase 0.02U, U6 tailed promoter 5 ng, tracR tailed template 
5 ng and gRNA oligos 0.02 µM in HF buffer according to manufacturer’s instructions, total 
volume 100 µl. 5 ng of each linker primer was used, depicted in Tables 3 and 4.).  
 
Table 3. Guide cassette assembly PCR primers for EpCAM and ZNF486 
EpCAM plasmid Fw. Primer Rev. Primer 
EpCAM guide 1 1 aggc fw. 1 aggc rev 
EpCAM guide 2 2 aggc fw. 5 aggc rev. 
ZNF486 plasmid Fw. Primer Rev. Primer 
ZNF486 guide 2 1 aggc fw. 3 aggc rev 
ZNF486 guide 3 4 aggc fw. 5 aggc rev. 
Combination plasmid Fw. Primer Rev. Primer 
EpCAM guide 1 1 aggc fw. 1 aggc rev 
EpCAM guide 2 2 aggc fw. 2 aggc rev. 
ZNF486 guide 2 3 aggc fw. 3 aggc rev 
ZNF486 guide 3 4 aggc fw. 5 aggc rev. 
 
Table 4. Guide cassette assembly PCR primers for KLF2, KLF5 and KLF17. 




Screen guide Fw. 
Primer 
Rev. Primer 
KLF2 guide 1 1 aggc 
fw. 
1 aggc rev. KLF2 guide 1 1 aggc fw. 1 aggc rev. 
KLF2 guide 2 2 aggc 
fw. 
2 aggc rev. KLF2 guide 5 2 aggc fw. 2 aggc rev. 
KLF5 guide 1 3 aggc 
fw. 
3 aggc rev. KLF5 guide 1 3 aggc fw. 3 aggc rev. 
KLF5 guide 5 4 aggc 
fw. 
4 aggc rev. KLF5 guide 5 4 aggc fw. 4 aggc rev. 





KLF17 guide 3 5 aggc fw. 5 aggc 
continuation 
rev. 
KLF17 guide 6 6 aggc 
fw. 




Golden gate-ligation was then used to assemble five plasmids. Three of these plasmids 
were for EpCAM and ZNF486: two guide sequences were selected to a plasmid for 
ZNF486 activation, two guides for EpCAM activation plasmid and additionally all four 
sequences were inserted to a singular EpCAM & ZNF486 -plasmid. Two clones were 
made for each plasmid with E. coli transfection. 
 
Additionally, Golden gate -ligation was used to assemble two more plasmids for KLF2, 
KLF5 and KLF17. First plasmid contained guides selected by RT-qPCR results and the 
second contained guides selected by earlier screens. The cassettes were assembled using 
a PCR (T4 DNA ligase 5 U, Esp3l Restriction enzyme 10 U, DTT 10 mM, GG-dest 
plasmid 150 ng and guide cassettes 50 ng each in T4 ligase buffer according to 
manufacturer’s instructions, total volume 20 µl). Reaction was run at 37 °C for 2 min, 16 
°C for 5 min and 80 °C for 20 min, 50 cycles. 
 
3.2.2 Plasmid cloning using e.coli 
10 μl of GG-dest plasmid DNA was transfected to 66 μl of competent DH5-α E. coli cells 
(New England Biolabs, NEB5) by incubating the cells on ice for 30 min, and heat 
shocking them using a heat block at 42 °C for 1 min, returning the cells on ice for 1 min. 
The solution was spread on pre-made ampicillin-LB coated petri dishes, and left to 
incubate in 37 °C for 16 hours overnight. 
The next day, two colonies were picked from each plate using a pipette tip, and 
submerged to 5 ml of LB media supplemented with 5 μl of ampicillin. 
 
3.2.3 Plasmid restriction and ligation 
In order to transfect the guides into fibroblast cells, the guide insert was isolated from the 
GG-dest backbone and ligated into a GG-EBNA backbone (GG-EBNA plasmid solution 
1 µl, insert sequence solution 1 µl, T4 DNA ligase 5U in T4 DNA ligase buffer according 
to manufacturer’s instructions, total volume 10 µl). To confirm band sizes and to ensure 
compatible ends for joining inserts and plasmid backbones, the plasmid DNA was 
digested with restriction enzymes Notl and EcoR1 (Plasmid DNA 800 ng, Notl 5U and 
EcoRl 5U in FastDigest Green buffer according to manufacturer’s instructions, total 
volume 10 µl). For GG-dest and GG-EBNA digestion, 800 and 500 ng of plasmid was 
used, respectively. The reaction was incubated in 37 °C for 30 min. For band size 




3.2.4 Plasmid isolation using miniprep and midiprep 
The plasmids were isolated using GeneJET Plasmid Miniprep Kit (Thermo Scientific, 
K0503), and stored in -20 C, and later using NucleoBond Xtra Midi EF (Macherey Nagel, 
740420.50). The DNA concentrations were measured using SimpliNano 
spectrophotometer (Table 5.). 
 
Table 5. Plasmid concentrations 
 for EpCAM and 
ZNF486 
C (ng/ul) Cassettes for KLF2, KLF5 
and KLF17 
C (ng/ul) 
EpCAM clone 1 153.7 qPCR clone 1 206.0 
EpCAM clone 2 204.7 Screen clone 1 150.9 
ZNF486 clone 1 259.0 Screen clone 2 170.0 
ZNF486 clone 2 167.8 Screen clone 3 185.4 
Combination clone 1 210.8 Screen clone 4 174.1 
Combination clone 2 209.0 Screen clone 5 187.5 
 
3.2.5 Glycerol stocks 
The prepared E. coli cultures containing transformed plasmids were preserved as 2 ml 
Eppendorf’s stocks, with 1:4 glycerol (400 ul) and 3:4 bacterial culture in LB (1200 ul). 
The stock tubes were stored in -80 C. 
 
3.2.6 Sanger sequencing 
5 μl of 80-100 ng/ul template plasmid DNA was mixed with 5 μl of 100 μM primer 
solution. Different sample was prepared for each primer. Samples were sent to Eurofins 
Genomics for sequencing (LightRun Tube Service). To sequence EpCAM and ZNF486, 
T7 forward and SP6 reverse primers were used. For KLF2, KLF5 and KLF17, primers 
were made from the sequences of KLF5 g5 in forward, KLF5 g5 in reverse, KLF17 g3 in 
reverse, T7 forward primer and a Bbsl reverse sequence to substitute for a possibly faulty 




Table 6. Sanger sequencing primers 
Primer Sequence 
KLF5 g5 forward GCCCGACCGCACCCCTCTC 
KLF5 g5 reverse GAGAGGGGTGCGGTCGGGC 
KLF 17 g3 reverse ATTCCACCCCTCAGTCTGA 
Bbsl reverse ATGGCTGATTATGATCTAGAGTC 
T7 forward TAATACGACTCACTATAGGG 
SP6 reverse ATTTAGGTGACACTATAG 
 
 
3.3 Cell culturing 
3.3.1 Cell cultures 
Human foreskin fibroblasts (HFFs) and human embryonic kidney 293 -cells (HEK293s) 
were grown in Mouse embryonic fibroblast (MEF) -media. The cells were cultured on 
BioLite cell culture dishes (Thermo Scientific™, 130182) or Costar 6-, 12-, 24-well cell 
culture plates (Corning, 3335-7). Cells were passaged when confluency reached 80 %. 
For this, the cells were submerged in TrypLE™ (Gibco™, 12604021) for 3 min at 37 C, 
and the plated were gently tapped to dislodge the cells. Cell media 2 times the volume of 
TrypLE™ was added to neutralise the trypsinisation, and the suspension was centrifuged 
for 4 min at 200 g. The supernatant was removed, and cells were resuspended in MEF-
medium on a cell culture dish at a ratio of 1:20 to 1:40.  
 
LCL cells were cultured in 150 cm2 cell culture flasks (Corning, CLS430825-50EA), 
using LCL medium (RPMI 1640 Medium (Gibco™, 11875093) supplemented with 
GlutaMAX™, 15% FBS and 1 μM Sodium Pyruvate (Lonza, BE13-115E). The cells were 
passaged by first centrifuging them in a falcon tube at 200 g for 5 min, and then 
resuspended in 1ml PBS. The cell density was counted using Countess Automated Cell 
Counter (Invitrogen™), with 10 μl of cell suspension and 10 μl of 0.4% Trypan Blue 
Stain (Invitrogen™, T10282) on the counting slide. A cell density of 0.5 – 1.5 x 106 






3.3.2 Cryopreservation and thawing of cells 
Cells were thawed by hand and centrifuged at 200 g for 5 min. The cells were then washed 
by resuspension to PBS and the centrifugation was repeated. The pellet was then 
suspended to the used cell media and incubated on culture dishes in 37 C.  
 
To freeze the cells, they were first detached submerging them in TrypLE™ for 3 min at 
37 °C. The plate was tapped lightly to dislodge the cells and centrifuged in a falcon tube 
for 4 min at 200 g. The pellet was suspended in 0.5 ml cell medium and 0.5 ml freezing 
medium (80 % fetal bovine serum (FBS) and 20 % dimethyl sulfoxide, (DMSO, Sigma, 
D8418-100ML), for a total DMSO concentration of 10 %). The cell suspension was then 




3.4 Transfection and reprogramming 
3.4.1 LCL transfection and reprogramming 
LCL cells were transfected with electroporation using Invitrogen Neon -transfection 
system with 1650 V, 10 ms with 3 x pulse, and seeded on matrigel on 6-well plates in 2 
ml LCL media per well with 0.25 mM Sodium butyrate (NaB) (Table 7.). On day 3, the 
transfected cells were passaged to 2 ml new LCL media with 0.25 mM NaB, by pelleting 
cells with 200 g centrifugation for 5 min, and counting 500 000 cells for every 1 ml of 
media. For the counting, Countess automatic cell counter was used with 10 μl of cell 
suspension and 10 μl trypan blue for each counting plate. From day 6 onwards, cell media 
was changed to every 2 days with the same method, except using hES (human Embryonic 
Stem cell)-media with 0.25 mM NaB. From day 10, all non-adherent cells were removed 
from the wells, and 2 ml E8 media without NaB was added for each well. The E8 media 










Table 7. Conditions for LCL transfections 
EEA Plasmid C (µg) -EEA Plasmid C (µg) 
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3.4.2 HFF transfection and reprogramming 
HFF cells were transfected with electroporation using Invitrogen Neon -transfection 
system with 1650 V, 10 ms with 3 x pulse, and seeded on matrigel on 10 ml petri dishes 
10 ml MEF-media per well with 0.25 mM Sodium butyrate (NaB) (Table 8.). Cell media 
was changed every other day. From day 4 onwards, the cell media was changed to 1:1 
ratio of MEF to hES media with 0.25 mM NaB. On day 16, E8 flex-media was changed 















Table 8. Conditions for HFF transfections 
EpCAM plasmids C 
(µg) 
EEA plasmids C 
(µg) 
TdT Plasmids C (µg) 
GG-EBNA-EPCAM 1.5 GG-EBNA-EEA-
5g-PGK-Puro 


























   
 
 
3.5 iPSC characterization 
3.5.1 Alkaline Phosphatase Staining 
The reprogrammed LCL-colonies at day 21 were washed with PBS once and fixed in 4 
% paraformaldehyde (Fisher Chemical, 10131580) for 15 min RT in 1x PBS. The cells 
were then washed with PBS twice times and strained with NBT/BCIP solution (Tris-HCl 
pH 9.5 100mM, NaCl 100mM, MgCl2 50mM, NBT/BCIP stock (Sigma-Aldrich) 20 µl 
in water) for about 10 minutes each or when colonies were clearly visible. The solution 
was then replaced with PBS and the wells were scanned and counted. 
 
3.5.2 Immunocytochemistry 
Visualization of expressed genes was done with immunocytochemical staining. The cells 
were fixed in 4 % paraformaldehyde for 15 min, permeabilized with 0.5 % triton-X in 
PBS for 10 min and blocked with Ultra V Block for 10 min. Cells were then incubated 







Table 9. Primary antibodies for immunocytochemical staining: 
Primary 
Antibody  
Manufacturer  Host Species  Dilution  Catalog  
NANOG  Cell signaling 
technologies  
Rabbit  1:250  4903S  
OCT4  Santa Cruz 
Biotechnology 
Rabbit  1:500  SC-9081  
TRA-1-60  Invitrogen  Mouse 1:200 MA1-023 
TRA-1-81 Invitrogen Mouse 1:200 MA1-024 
 
 
After the primary antibodies were aspirated, the cells were washed with PBS. Cells were 
then incubated with the secondary antibody in 0.1 % tween in 1:500 ratio for 30 min RT 
(Table 10.). After this, secondary antibodies were aspirated, and the stained cells were 
immersed in DAPI and imaged with fluorescence microscope. 
 




Manufacturer  Host Species  Dilution  Catalog  
Hoechst  Thermo Fisher 
scientific  
















Invitrogen  Donkey  1:500  A21206  
 
 
3.5.3 Embryoid body formation 
The iPSC colonies were detached in EDTA for 3 min, and transferred to non-adherent 
dishes (Corning, 3471) in hES-medium (KnockOut DMEM; Gibco), supplemented with 
20 % KnockOut serum replacement (Gibco), 1 % GlutaMAX supplement (Gibco), 0.1 
mM beta-mercaptoethanol (Gibco) and 1 % non-essential amino acids (Gibco), without 
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bFGF. Cell media was changed every other day. For this, cells were carefully transferred 
to 10 ml falcon tubes, and pelleted on 200 rpm for 4 min. After aspirating media, cells 
were suspended in 1 ml hES without bFGF and transferred back to non-adherent dishes 
in 4 ml media. On day 11, some embryoid bodies were plated on gelatin-coated 24-well 
dishes. On day 4 from plating, embryoid bodies were fixed in 4 % PFA for 30 min RT, 
submerged in PBS, and moved to +6 °C. On day 10, fixed embryoid bodies were 
incubated with primary antibodies in +6 °C o/n (Table 11.).  
 




Manufacturer Host species Dilution Catalog 
Sox17 R&D Systems Goat 1:500 AF1924 
α-smooth muscle 
actin 
Sigma Mouse 1:500 A2547 
β-tubulin III Abcam Rabbit 1:500 Ab18207 
 
 
Afterwards, cells were gently washed with PBS, incubated with secondary antibodies 
(Table 12.), and imaged for SOX17, α-SMA (α- smooth muscle actin) and TUBB3 (β-
tubulin III). 
 




Manufacturer  Host Species  Dilution  Catalog  
Hoechst  Thermo Fisher 
scientific  





















3.6 Statistical analysis 
To analyse RT-qPCR data, comparative delta Ct method was used. This method 
normalises the Ct-values to a chosen housekeeping gene, in this case Cyclophilin G 
(ΔCtT). Additionally, it normalized them to a calibrator standard (Golden control VI, 
ΔCtC). The housekeeping gene is subtracted from the resulting activation values. Then 
the normalized golden control value is subtracted from normalized activation value.    
In the case of EpCAM & ZNF486, the guides were also normalized to NT control to 
give fold change. In the case of KLF2, KLF5 and KLF17, the guides were normalized 
to their respective pools in addition to Cyclophilin G and Golden control.  
In inductions, AP-positive colonies were counted by hand. Clear, moderately sized 
colonies were counted as positive, while ambiguous dots were left out (Fig 14.).   
Error bars in both experiments represent the standard error mean (SEM). Single factor 
ANOVA was used to evaluate the significance level. 
 
 
3.7 Cell Imaging 
Cells were monitored with Tissue Culture microscope (Leica Miscrosystems, DM IL 
LED). Images were taken with an attached Leica EC3 digital camera with Leica LAS 
EZ software. Fluorescent images were taken with Evos FL cell imaging system (Life 
Technologies). Colour detection was done via installed DAPI, GFP and Texas red light 
cubes. Images were processed with Adobe photoshop to optimize brightness and 






The CRISPRa reprogramming method can be optimized by screening for guide RNAs 
that improve the reprogramming outcome. Guides that promote more efficient 
reprogramming are expected to enrich in the reprogrammed iPSC colonies. However, to 
rule out passenger guides that are randomly included in the reprogramming colonies, hits 
from the screen must be validated. The thesis work will be focused on validating the hits 
from a previously performed CRISPRa screen for guide RNAs that can enhance 
reprogramming. The guide RNAs will first be assessed for their efficiency in activating 
their target genes, followed by assessing their effect on pluripotent reprogramming 
efficiency. 
 
4.1 HFF-cell line characterization 
HFF cell lines induced with OSKML and CRISPR-activator were characterized for their 
reprogramming capability by the expression of OCT4 and NANOG using 
immunocytochemical staining. This was done to create a cell line known to be capable 
of pluripotency reversal using CRISPRa and endogenous target expression. On day 14, 
all cell lines showed positive for pluripotency markers OCT4 and NANOG, and cell 
surface markers TRA-1-60 and TRA-1-81 (Fig 1. a and b) The cells were also 
developed into suspended embryoid bodies and allowed to differentiate. The cells were 
then stained for markers SOX17, α-smooth muscle actin and β-tubulin III using same 





Figure 1. HFF cell line characterization. Expression of pluripotency markers in 
reprogrammed HFF iPSC colonies. Co-staining of NANOG, TRA-1-81 and DNA (a), as well as 
OCT4, TRA-1-60 and DNA (b). Picture c) depicts expression of germ layer-speicific markers in 
embryoid bodies. Ectodermal (β-tubulin III), mesodermal (α-smooth muscle actin) and 
endodermal (SOX17). Scale bars = 400 µM 
 
 
4.2 Guide assembly and HEK293 transfection 
Five plasmids targeting EpCAM and 5 plasmids targeting ZNF486 were designed in 
Benchling. As for KLF2, KLF5 and KLF17, guide oligos were already made in previous 
experiments and were extracted and donated by a colleague for use. Five guides were 
used for KLF2 and six guides for KLF5 and KLF17 each. 
The plasmids were first assembled into cassettes using PCR. Successful guide assembly 
was confirmed with electrophoresis (Fig 2.). Assembled guides were then transfected into 
HEK293 cells, alongside a dCas9 activator-encoding plasmid. A non-transfected control 















A sample was made for each guide plasmid, and pool samples were made for each gene, 
containing all five guides for the given gene. These pools were used as a common 
parameter to normalize the five genes to. Three biological replicates were used. Three 
days later the cells were lysed, and the resulting lysate RNA was reverse transcribed into 




Figure 2. Guide assembly test. Electrophoresis was used to confirm successful guide assembly 
for KLF2, KLF5, KLF17 (a) and for ZNF486 and EpCAM (b). In c), EpCAM guide 2 was 
reassembled as it did not show correctly in first PCR.  
 
After HEK293 transfections and RNA extraction, the gene activation levels of ZNF486 
and EpCAM for single guides and pools was tested with PCR (Fig 3. a and b). This was 
to see whether noticeable gene activation could be observed and see if performing RT-
qPCR can be considered viable. For KLF2, KLF5 and KLF17, expression levels of pools 
were tested using the same method (Fig 3. c). Sometimes residual DNA left over from 
the extraction can interfere with qPCR results. To see if this residual DNA is present, 
cDNA conversion was repeated using a control sample without reverse transcriptase 










Figure 3. Single guide activation PCR, pool activation PCR and DNA interference PCR. 
PCR was used to confirm single guide gene expression and pool gene expression to see if the 
expression levels are sufficient for RT-qPCR. PCR for ZNF486 (a) and EpCAM (b). PCR for 
pool expression levels for KLF2, KLF5, KLF17 (c). DNA interference PCR for KLF2, KLF5 and 
KLF17 (d). RT depicts sample with reverse transcriptase, -RT depicts sample without. 
 
 
4.3 Guide RT-qPCR analysis 
To validate the CRISPRa gene expression upregulation, the sample cDNA was amplified 
using RT-qPCR. Samples were compared to the NT control. The expression was also 
normalized to a housekeeping gene (in this case Cyclophilin G), to see if the expression 
was different from a cells baseline expression. In addition, samples were normalized to a 
Golden Control -DNA sample, which served as a reference point across all replicates. In 
addition to the three biological replicates, two technical replicated were made by the RT-
qPCR process. DNA obtained from iPSC cells was used to test the qPCR primers’ 
attachment to their targets, as iPSC DNA is expected to contain small amounts of the 












Figure 4. Primer attachment test. PCR to validate the qPCR primers’ attachment to their target 
sequences in D0 iPSC DNA. (a) for KLF2, KLF5, KLF17 and (b) for ZNF486 and EpCAM. 
 
 
4.4 EpCAM guides resulted in increased gene activation 
The results show the highest expression in EpCAM guide 1, which then diminishes 
gradually towards guide 5 (Fig 5. a). This also suggests a correlation between the guide’s 
distance from the promoter and its effectiveness. Guides were designed from the closest 
(guide 1), to farthest (guide 5) from the promoter. EpCAM guides 1 and 2 thus showed 
the highest efficiency and were selected for plasmid assembly and cloning for the 
following reprogramming. In the case of ZNF486, there were no clear differences in the 
guide-induced expression levels compared to the NT-control (Fig 5. b). ZNF486 guides 
2 and 3 were selected nevertheless for plasmid assembly and cloning, as they seemed 
















Figure 5. Gene activation levels of EpCAM and ZNF486 guides in HEK293 cells. a) Gene 
expression levels of EpCAM targeting guides and a pool containing all 5 guides compared to non-
transfected control. (Single factor ANOVA *p = 0,000213, significant mean difference indicated 
by ´***´). b) Gene expression levels of ZNF486 targeting guides and a pool compared to a non-
transfected control. (Single factor ANOVA *p = 0,987, non-significant mean difference indicated 
by ´ns´). Both genes were normalized first to Cyclophilin G housekeeping gene and the to Golden 
control DNA. Genes were then normalized again to NT for fold change. Error bars depict standard 
error mean of all three replicates. 
 
 
4.5 Screen-selected candidate guides showed greatest activation in KLFs 
In the case of Krüppel-like factors, KLF2 showed greatest activation in guides 1 and 2 
(Fig 6. a), KLF5 in guides 1 and 5 (Fig 6. b), and KLF17 in guides 3 and 6 (Fig 6. c), 
although the variance between replicates of KLF17 was significant. These guides were 
then compared to guides enriched in guide screening experiments (Fig 6. d). The purpose 
of this was to give insight on how accurately these guide screens would reflect the gene 
activation potential of the enriched genes, and whether this method could be used to select 
guides for activation in subsequent experiments. Comparing the two sets of guides, we 
can see that 4 out of 6 guides in the RT-qPCR analysis correspond to their screen 
equivalents. Thus, guides enriched in screens seem to typically enrich along with their 
gene activation potential. This should theoretically also relate to the pluripotency 
inducing potential of their respective genes. Like with EpCAM, the guide closest to the 
promoter site (guide 1), was the most selected single guide of all the guides both in screens 








































Figure 6. Gene activation levels of KLF2, KLF5 and KLF17 guides in HEK293 cells.  a) 
Gene expression levels of KLF2 targeting guides and a pool containing all 5 guides compared to 
non-transfected control. (Single factor ANOVA *p = 1,6e-12, extremely significant difference 
indicated by ´****´) b) Gene expression levels of KLF5 targeting guides and a pool compared to 
non-transfected control. (Single factor ANOVA *p = 1,13e-19, extremely significant difference 
indicated by ´****´) c) Gene expression levels of KLF17 targeting guides and a pool compared 
to non-transfected control. All genes were normalized first to Cyclophilin G housekeeping gene 
and the Golden control DNA. (Single factor ANOVA *p = 0,294, non-significant mean difference 
indicated by ´ns´) d) Comparison of guides enriched in screens and guides with the highest 
activation in RT-qPCR for KLF2, KLF5 and KLF17. Guides were normalized to their pools. Error 
bars depict standard error mean of all three replicates. 
 
 
4.6 ZNF486 & EpCAM cloning 
The selected guides were assembled into three plasmids using Golden gate -ligation, with 
one containing EpCAM g1 and g2, second ZNF486 g2 and g3, and third containing all 
four guides (EpCAM g1, g2, ZNF486 g2, g3). The plasmids were first cloned in E. coli, 
and guide inserts were then inserted into EBNA backbone for another cloning and 
subsequent electroporation. In each step, correct band sized were confirmed with 
electrophoresis from EcoRI- and SpeI- digested minipreps (Fig. 7). Final midiprep 
preparations from plasmids were confirmed with sanger sequencing and made into 
glycerol stocks. However, it was decided that due to the gene activation of  ZNF486  
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Figure 7. Digestion of GGdest- and EBNA plasmid clones for EpCAM and ZNF486 in E. 
coli. a) Guide assembly PCR of individual guides for Golden Gate -ligation. b) Ggdest-backbone 
miniprep digestion samples, two clones per plasmid. c) EBNA-backbone digestion samples. d) 
EBNA backbone miniprep digestion. e) Final EBNA-backbone MIDIprep digestion. In photos, 
EpCAM clones contain EpCAM guides 1 and 2, ZNF486 clones contain ZNF486 guides 2 and 3, 
and Z & E clones contain all four guides.  
 
 
4.7 KLF Cloning 
In the case of Krüppel-like factors, two distinct plasmids were made. The first plasmid 
contained all 6 guides selected by the RT-qPCR analysis. The second plasmid contained 
all 6 guides selected based on earlier screens. Following the same methodology as with 
ZNF486 and EpCAM, guides were first inserted into GG-dest backbone followed by 
EBNA backbone. During all steps, correct band sized were confirmed by digestion and 
electrophoresis (Fig 8.). Results of guide assembly PCR also show additional dim bands. 
Given their small size, these are thought to be interlocked primer sequences. Final 
midiprep preparations from plasmids were confirmed with sanger sequencing and made 






























Figure 8. Digestion of GGdest plasmid clones for KLF2, KLF5 and KLF17 in E. coli. a) & 
b) Guide assembly PCR of individual guides for Golden gate -ligation. c) Ggdest-backbone 




4.8 EpCAM expression resulted in negligible pluripotent colonies in LCL cells 
To determine the effects of EpCAM in reprogramming efficiency, LCL cells were 
electroporated with dCas9 CRISPR-activator (pCXLE-dCas9VP192-T2A-EGFP-shP53 
plasmid), endogenous OSKML activating guides, EpCAM guide plasmid and an EEA 
plasmid. A sample without EEA was used as a control. Three replicates were made. The 
cells were compared to CRISPRa + miRNA302 guide plasmid inductions. Transgene 
reprogramming was used as a positive control. Plasmids used in each electroporation are 
summarized in Table 13. LCL cells electroporated with plasmids containing the dCas9-
activator and guide plasmids were evaluated by their GFP expression three days later (Fig 
9. a). Cells treated with EpCAM seemed to grow faster than controls, but their 
morphology changed towards iPSC morphology slower. EpCAM samples still had 
attached cell clusters at day 21. Cells not treated with EEA also had a more differentiated 














with EEA or without showed a very limited amount of colony formation, compared to 
transgene and miRNA302 samples (Fig 9. b, c and d). CRISPRa in the absence of EEA 
unexpectedly showed also no colony formations whatsoever. This could indicate a 
mistake in inductions. Whether this would also affect EpCAM sample colony formation 
is to be speculated.  
 
Electroporation Plasmids 
CRISPRa - pCXLE-dCas9VP192-T2A-EGFP-shP53 (Addgene #69535) 
- GG-EBNA-MIR302g7-PGK-Puro 
- GG-EBNA-O3S2K2M2K2L1-PP (Addgene #102902) 
Transgene - pCXLE-hOCT3/4-shp53-F (Addgene #27077) 
- pCXLE-hSK (Addgene #27078) 
- pCXLE-hUL (Addgene #27080) 
CRISPRa + EEA - pCXLE-dCas9VP192-T2A-EGFP-shP53 (Addgene #69535) 
- GG-EBNA-MIR302g7-PGK-Puro 
- GG-EBNA-O3S2K2M2K2L1-PP (Addgene #102902) 
- GG-EBNA-EEA-5guides-PGK-Puro (Addgene #102898) 
EpCAM - pCXLE-dCas9VP192-T2A-EGFP-shP53 (Addgene #69535) 
- GG-EBNA-MIR302g7-PGK-Puro 
- GG-EBNA-O3S2K2M2K2L1-PP (Addgene #102902) 
- GG-EBNA-EPCAM 
EpCAM + EEA - pCXLE-dCas9VP192-T2A-EGFP-shP53 (Addgene #69535) 
- GG-EBNA-MIR302g7-PGK-Puro 
- GG-EBNA-O3S2K2M2K2L1-PP (Addgene #102902) 
- GG-EBNA-EPCAM 
- GG-EBNA-EEA-5guides-PGK-Puro (Addgene #102898) 
Table 13. Electroporation conditions for LCL cells. Plasmids transfected for each 







Figure 9. Comparison of reprogramming efficiency in LCL cells between samples 
reprogrammed using EpCAM without EEA, EpCAM with EEA, miRNA, just CRISPRa, 
and using transgenes. a) GFP fluorescence of LCL cells at day 3. Scale bars = 400 µM b) 
Difference in cell morphology between EpCAM with and without EEA at day 21. Scale bars = 
EpCAM + EEA EpCAM + EEA EpCAM 
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400 µM c) Alkaline phosphatase-stained colonies with 1.0 x 106 electroporated cells. d) Number 
of reprogrammed colonies for each method. (Single factor ANOVA, between EpCAM, EpCAM 
+ EEA and Transgene *p = 1,03e-05, between Transgene and CRISPRa + EEA *p = 0,000753, 
between EpCAM, EpCAM + EEA, CRISPR + EEA *p = 0,0015).  
 
 
4.9 EpCAM expression did not cause an increase of pluripotent colonies in 
HFF cells 
Additionally, the effect of EpCAM along with a dCas9 activator plasmid was tested on 
HFF cells. Plasmids used in each electroporation are summarized in Table 14. From early 
on, EEA treated cells seemed to form pluripotent colonies faster than EpCAM or TdT 
samples. Otherwise, their morphology did not seem to differ noticeably. From the results 
can be seen that the control EEA samples effectively created iPSCs, with approximately 
100 colonies on each plate, except for one plate which appears to have failed (Fig 10.). 
Negative TdT control likewise brought up just several individual colonies, as expected. 
However, on EpCAM-induced samples only one or two colonies can be seen, indicating 
that endogenous expression of EpCAM on HFF, and possibly on LCL cells, does not 




EpCAM - pCXLE-dCas9VP192-T2A-EGFP-shP53 (Addgene #69535) 
- GG-EBNA-MIR302g7-PGK-Puro 
- GG-EBNA-O3S2K2M2K2L1-PP (Addgene #102902) 
- GG-EBNA-EPCAM 
EEA - pCXLE-dCas9VP192-T2A-EGFP-shP53 (Addgene #69535) 
- GG-EBNA-MIR302g7-PGK-Puro 
- GG-EBNA-O3S2K2M2K2L1-PP (Addgene #102902) 
- GG-EBNA-EEA-5guides-PGK-Puro (Addgene #102898) 
TdT - pCXLE-dCas9VP192-T2A-EGFP-shP53 (Addgene #69535) 
- GG-EBNA-MIR302g7-PGK-Puro 
- GG-EBNA-O3S2K2M2K2L1-PP (Addgene #102902) 
- GG-EBNA-TdT 
Table 14. Elektroporation conditions for HFF cells. Plasmids tranfected for each 







Figure 10. Comparison of reprogramming efficiency in HFF cells between samples 
reprogrammed using EEA, EpCAM or TdT. a) Difference in cell morphology between 
samples at day 21. Scale bars = 400 µM b) Alkaline phosphatase stained colonies with 1.0 x 106 
electroporated cells. c) Number of reprogrammed colonies for each method. (Single factor 
ANOVA between EEA and EpCAM *p = 0,0998, non-significant mean difference indicated by 
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Fig 11. Zoom in of EEA-treated HFF cells. Medium sized colonies resembling iPSC 
morphology were counter as a reprogrammed colony, example circled in red. Very small specks 

















5.1 Selected guides increase endogenous expression 
By validating the gene activation levels of screened guide RNAs we aimed to find the 
two most effective guides for pluripotency factor activation. Additionally, for KLF2, 
KLF5 and KLF17 we aimed to confirm that the enriched guides were also mostly the ones 
that best increased gene expression, and likely thus has an effect on reprogramming 
outcome. This needs to be confirmed on later studies. 
All 5 target genes were successfully transfected into HEK293 cells, which caused 
endogenous activation of the targeted genes. The expression levels of the obtained sample 
DNA was then validated using RT-qPCR. All genes, with the exception of ZNF486, 
showed clear differences in activation levels compared to the non-transfected control, 
with a trend for sites closer to the promoter site to show more activation than the ones 
further away. This makes sense, as a closer promoter site likely allows for a more efficient 
contact for the transcription machinery to initiate transcription. However, the interaction 
between CRISPRa and factors aiding in transcription is not well established, and can 
affect the gene expression in unexpected ways. The differing gene activation could be 
affected by blocking of the transcription factors based on the position of the guide 
sequences. Pool samples, as expected, showed the highest activation. However, using too 
many endogenous guides at the same time can have diminishing effects on activation, and 
as such these pool samples of five to six guides are likely thus not optimal for pluripotency 
induction. Best effects are expected to be observed by pooling together 2 of the best 
activator guides for each given gene.  
 
5.2 Enrichment reflects guides’ gene activation potential 
In the case of KLF2, KLF5 and KLF17, four of the six guides which caused highest gene 
activation in RT-qPCR experiment, also were the ones enriched in the earlier guide 
screening. These guides were the KLF2 guide 1, KLF5 guides 1 and 5, and KLF17 guide 
3. On RT-qPCR, KLF2 guide 2 however shower higher activation in contrast to the 
enriched guide 5, as was the case with KLF17 guide 1, which was replaced with guide 6 
in screens. As such, this indicates that screening guides in bulk by enrichment levels 
reflects their gene activation levels by most part, and could be used for finding candidate 
guides for pluripotency enhancement. All enriched guides however caused activation of 
the target genes, although enriched KLF2 guide 5 and KLF17 guide 1 showed small or 
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no difference compared to the non-transfected control. For what reason these particular 
genes were enriched compared to the better ones in RT-qPCR remains to be answered. 
As the enrichment in screens ultimately reflects the genes’ impact on the pluripotency 
outcome, this might be part due to arbitrary differences with the guides’ effects in regards 
to the final pluripotent state. There also tends to be a limit to how much gene activation 
is useful, and smaller endogenous activation could be enough to get the full potential. 
This could be experimented by testing different guides separately in pluripotency 
inductions, however it needs to be considered whether this is practical. Additionally, as 
the guides were screened for their effects in bulk, some non-acting guides might affect 
the efficacy of other guides, enhancing the reprogramming process indirectly. There 
could be potential in researching the guide combinations, which enriched a particular 
colony, together. This could give insight to potential co-acting genes in the pluripotency 
network. Additionally, to see how these guide sets derived from different activation 
experiments differ in pluripotency enhancement would be interesting to see in the future. 
As the difference is only between two guides out of six, and accounting for the possible 
negligible effects between guides, the end result would likely be not much different. 
Whether the three screened KLF guides enhance the pluripotency in general in addition 
to the typical OSKML factors is also an important aspect to see. 
 
5.3 EpCAM did not enhance pluripotency in LCL and HFF cells using 
CRISPRa 
Introducing EpCAM to either LCL or HFF cells during the reprogramming process, 
EpCAM did not seem to enhance the reprogramming. On the contrary, it seemed to inhibit 
pluripotency generation somewhat. This difference was not however statistically 
significant in LCL cells, but compared to transgene and CRISPRa + EEA inductions in 
HFF cells a significant difference can be seen. Amongst the LCL controls, the failed 
CRISPRa transfection caused some suspicion if the transfections failed. However, other 
inductions showed expected results, and the following HFF transfections showing similar 
lack of EpCAM induced iPSCs, it is possible that the transfections worked but just were 
not able to induce pluripotency.  
 
The cells were successfully cultivated with the typical CRISPRa reprogramming protocol 
by integrating the DDdCas9VP192 activator along with the OSKML transcription factor 
-targeting guides, using NaB. EpCAM, negative TdT control and positive EEA control 
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grew normally with no great differences, except that EEA-induced cells created 
pluripotent colonies faster. We hypothesized that as EEA induction has been observed to 
greatly enhance the pluripotency, and TdT should not cause pluripotency enhancement, 
cells induced with EpCAM alone should reside within EEA and TdT controls (Weltner 
et al., 2018b). However, EpCAM induced HFF cells showed even less reprogrammed 
colonies than TdT. This is unexpected, as EpCAM has been shown earlier to enhance 
pluripotency in fibroblasts (H. P. Huang et al., 2011; Kuan et al., 2017). As the experiment 
showed similar results in two different occasions with distinct cell types, it raises the 
question whether this particular method of CRISPR activation or the inducible activators 
themselves counter this enhancement of reprogramming.  
 
5.4 EpCAM in reprogramming 
EpCAM has been observed to increase c-Myc expression in both epithelial cells and 
fibroblasts and increase cancer cell proliferation (Münz et al., 2004). As c-Myc is a 
common pluripotency factor, EpCAM was expected to increase reprogramming 
efficiency (Münz et al., 2004). This has also been confirmed with previous experiments 
involving EpCAM in reprogramming (H. P. Huang et al., 2011). EpCAM has also been 
observed to increase OCT4 expression, inhibit the p53 pathway and increase 
reprogramming efficiency in fibroblasts (H. P. Huang et al., 2011; Kuan et al., 2017). 
Why EpCAM seemed to inhibit pluripotent reprogramming in this case is not known. The 
role of EpCAM in cell development is complex, and is known to be relevant in 
proliferation and differentiation of cells, also during gastrulation (L. Huang et al., 2018). 
Additionally, in adult cells, it is exclusively expressed in epithelial cells, and thus its 
effects might differ in the reprogramming of different cell types (Keller et al., 2019). 
 
One obvious explanation is that both of these induction experiments simply failed. 
According to electrophoresis experiments and sanger sequencing, upregulation of 
EpCAM using guides was present, and incorporation of EpCAM-targeting guides into 
inducible plasmids was successful. In this case, the fault would likely reside in 
unsuccessful electroporation. However, the cells managed to survive in same quantities 
across samples and the development of all different cell samples was roughly similar. 
There were some differences, however.  
In LCL cells, the morphology of EpCAM only induced cells started to resemble 
differentiated cells earlier than in EpCAM + EEA cells. The proliferation was also faster. 
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In HFF cells, EpCAM only induced cells showed normal development and morphology 
resembling pluripotency. The cells formed somewhat larger colonies compared to EEA 
and TdT, although not by a large margin. 
 
In LCL cells, it is possible that EpCAM induced cells developed faster, but were kept for 
too long, resulting in faster differentiation compared to EpCAM + EEA cells. According 
to previous studies, the development of EpCAM induced stem cells did not differ 
dramatically, and were able to efficiently induce pluripotency in roughly the same 
timeframe. However, these studies have been done using fibroblasts (H. P. Huang et al., 
2011). At current state, pluripotency induction using EpCAM in LCL cells has not been 
researched, and the role of EpCAM in their developmental pathway might be different.  
 
In HFF cells, in which EpCAM reprogramming has been successful, the reason might be 
that the conditions for EpCAM cells was unsuitable because of some differences in the 
methodology involving CRISPR-activation. In addition, because the conditions required 
for different cell stages in reprogramming are different, cells developing at different 
speeds could fall into unsuitable cell media when following standard protocol. This could 
cause the cells to die faster. 
 
In both cases, these possible factors affecting pluripotent reprogramming outcome using 
EpCAM could be tested by several means. Firstly, by changing the cell media conditions 
for samples types individually based on their cell morphology, rather than sharing the 
timeframe within all samples types, and observing whether there are notable differences 
in their development. And secondly, by experimenting how induction with EpCAM and 
CRISPRa alone might affect the cell morphology, via for example ICC-staining for 
relevant markers. 
  
In addition, as there is not much research on EpCAM reprogramming using LCL cells or 
other blood cells, it would be useful to experiment whether these cells can be 
reprogrammed into iPSCs using EpCAM by other means. As the gene activation in this 
case is done by non-integrative plasmid electroporation, the transient EpCAM expression 
might drastically affect the outcome compared to a more stable expression. EpCAM, like 
other genes, can have differing effects depending on the pluripotent state. For this reason, 
an inducible EpCAM activation could be one notable method to test. 
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5.5 Future prospects 
Guide screening by enrichment appears to be applicable to find candidate guides which 
effectively upregulate their target genes. Theoretically this would also apply to their 
effect in the reprogramming outcome. In the future it could be valuable to test enriched 
guide sets and their co-acting effects. It would also be useful to determine if there are 
other causes which affect the guide enrichment. Additionally, the candidate genes 
resulting from screens were not limited to tested KLFs, and the other genes also need to 
be evaluated for their gene activation and effects in reprogramming. 
 
Of course, guides targeting KLF2, KLF5 and KLF17 evaluated here need to be tested in 
the future for their reprogramming enhancing effects too. KLF2 and KLF5 could also be 
used to test if they can replace endogenous KLF4 to achieve pluripotency.   
 
Further experiments are needed to evaluate whether EpCAM upregulation is applicable 
in a CRISPR-activation system. Likely the CRISPRa method has some slightly distinct 
mechanics compared to conventional methods which need to be addressed to fully 
utilize genes studied here. 
In addition, the cells generated via EpCAM reprogramming would need to be 
characterized in the future. AP-staining is not sufficient for determining the cell’s 
pluripotency, and as such the cells should be stained for their pluripotency markers via 
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